News
FDA does a 180, suspending use of Valneva's chikungunya vaccine
Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an about-face, banning the use of the shot in the United States. | Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq,
Valneva Shares Tumble After Chikungunya Vaccine License Suspended in U.S.
Valneva shares dropped after it said it will no longer be able to sell its chikungunya vaccine in the U.S. after reports linked the vaccine to adverse effects. Shares trading in New York were nearly 22% lower ahead of the morning bell at $9.09.
Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...
The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...
The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...
The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.
Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...
FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...
Investing.com - Jefferies has reduced its price target on Valneva SE (NASDAQ:VALN) to $14.00 from $18.00 while maintaining a Buy rating on the stock. Currently trading at $9.13, Valneva has shown ...
Asianet Newsable on MSN1d
Valneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The Impact
A nalysts on Monday expressed divergent opinions on vaccine company Valneva SE (VALN) after the firm said that the United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback